Fundraising FoxMRL Ventures Fund
Corporate VCCambridge · Pre-Seed–Seed · 6 people tracked
Find your way into MRL Ventures Fund
Sign up to see every warm intro you have to MRL Ventures Fund
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MRL Ventures Fund team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
MRLV is a science-first corporate venture fund focused exclusively on therapeutics across all modalities — from small molecules to cell therapies — with the potential to transform standards of care. It backs first- and best-in-class preclinical and early-stage (including seed) programs, evaluating them on underlying biology strength, translational data quality, a clear path to human proof-of-concept, and team and syndicate alignment. The fund does not require product or technology rights as a condition of investment, and explicitly excludes medical devices, diagnostics and digital health. It leads or co-leads with sustained capital up to $25M per company from concept through IND, takes active director/observer roles, and offers follow-on funding and access to MSD's R&D leadership and BD&L connectivity.
Source: firm website, verified Sep 27, 2026.
Team · 6 people
from the firm's website & curated & public directories
President and managing partner of MRL Ventures Fund with 20 years in life sciences spanning research, company building, and corporate and traditional venture. Previously held roles at Wellington Partners, Entrepreneurs Fund and Novartis' corporate venture arm; holds a Ph.D. from the University of Geneva and did postdoctoral work at Oxford.
Partner at MRLV with over 10 years across research, IP law, venture capital and private equity. Previously a partner at EQT and at LSP (now EQT Life Sciences); holds a Ph.D. from the International Graduate School in Molecular Medicine in Ulm.
Senior associate at MRLV since 2025 sourcing and evaluating early-stage biotech startups. Previously worked at Flagship Pioneering and held research roles at Eli Lilly and Repertoire Immune Medicines; holds a Ph.D. in chemistry from the University of Georgia and an MBA from NYU Stern.
What they invest in
from 33 of 43 portfolio companiesBiotech ×30Healthtech ×19Medical Devices ×12AI & Machine Learning ×8Deep Tech ×7Digital Health ×2Longevity ×2Advanced Manufacturing ×1
HQs:United States×23Australia×1Belgium×1Chile×1
Who they back
founder profiles across 16 portfolio companiesFounding team size:solo founder×82 founders×63 founders×14+ founders×1
Where their founders studiedfrom 12 founders with education data
Harvard Business School ×2
What their founders studiedfrom 12 founders with field-of-study data
Life Sciences ×5Chemistry ×3Business & Management ×2Medicine ×2
Where their founders worked beforefrom 14 founders with career history
Atlas Venture ×2MPM BioImpact ×2
Investments · 43 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 42023 · 32021 · 12020 · 32019 · 12015 · 116 dated
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactPappas CapitalRA CapitalTCG Crossover+5 more
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)inTillman Gerngross(Director)
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalGV (Google Ventures)Mission Bay CapitalMission BiocapitalSV Health InvestorsPolaris Partners
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Co-investors5AM VenturesAgent CapitalMPM BioImpactRoche Venture FundTCG CrossoverWellington Management
Invivyd is a biopharmaceutical company that develops antibody-based product candidates for the prevention and treatment of serious viral infectious diseases, combining viral surveillance and predictive modeling with antibody engineering.
BiotechHealthtechWaltham, US
Tillman U. Gerngross(Executive Officer, Director)Marc Elia(Founder)inLynn Connolly(Executive Officer)Eric Kimble(Executive Officer)inHalley Gilbert(Executive Officer)Rebecca Dabora(Executive Officer)in
Co-investorsBain Capital Life SciencesForesite CapitalGV (Google Ventures)Premji InvestRA CapitalFidelity Investments+6 more
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
Nello Mainolfi(Founder)inBruce Booth(Chair)in
Co-investorsAtlas VentureAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersNextech Invest+7 more
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)
Co-investorsGV (Google Ventures)HEALTHCARE ROYALTY PARTNERSOUP (Osage University Partners)RA CapitalAlphabetAtlas Venture+1 more
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.
BiotechHealthtechWaltham, US
René Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Christopher Frankenfield(Chief Financial and Operating Officer)inKatarina Luptakova(Chief Medical Officer)inPaul Clancy(Director)
Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesRA CapitalRiverVest Venture Partners+9 more
ATB Therapeutics is a biotech company developing bispecific antibody therapies and related immunological treatments.
BiotechHealthtechMedical Devices
Dr. Mark Throsby(Chief Executive Officer)
Co-investorsV-Bio VenturesVIVES PartnersEQT Life SciencesSambrinvestWallonie EntreprendreEQT
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsSofinnova VenturesvenBio PartnersCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+8 more
InduPro develops next-generation protein therapeutics by leveraging inherent and induced proximity to modulate disease biology, with a focus on ADCs and T-cell engagers.
BiotechDeep TechMedical DevicesSeattle, US
K. Chris Garcia(Scientific Founder)Prakash Raman(CEO)inAmanda J. Redig(Chief Medical Officer)inScott Lesley(President & CSO)inPamela Holland(SVP of Biology)inSally Johnson(Chief People Officer)in
Co-investorsThe Column GroupVida Ventures
Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.
BiotechHealthtechLongevityWaltham, US
Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)inLizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in
Co-investorsLongwood FundMPM BioImpact8VCOno Venture Investment, Inc.
Therini Bio is a biotechnology company developing fibrin-targeting therapeutics to treat neurological and ophthalmological diseases, leveraging scientific discoveries in neurovascular and neuroimmune mechanisms of disease.
BiotechDigital HealthHealthtechMedical DevicesSacramento, US
Katerina Akassoglou(Scientific Founder, Director of the Center for Neurovascular Brain Immunology and Professor of Neurology at UCSF and Gladstone Institutes)inKaterina Akassoglou, PhD(Scientific Founder)Leslie Schulze(Executive Officer)Tara Nickerson(Executive Officer, Director)in
BoardOlga Danilchanka(Director)inLaia Crespo-Martin(Director)
Co-investorsSanofi VenturesSV Health InvestorsAngelini VenturesDementia Discovery FundDolby Family VenturesMitsui Global Investment+2 more
Topo Therapeutics is a drug discovery company developing treatments targeting ion channels and transmembrane proteins for conditions such as pain, epilepsy, and CNS, pulmonary, and renal diseases.
BiotechHealthtechCambridge, US
Hui Tian(Executive Officer, Director)inMadgalene Moran(Executive Officer, Director)Magdalene Moran(Chief Executive Officer)
BoardBruce Bean(Director)James Jeffrey Goater, Jr.(Director)
Board seatKarin Kleinhans· per SEC Form D
Co-investorsSR One Capital ManagementThe Column Group
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)inJosh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Co-investorsDroia VenturesInkefMission BiocapitalNextech InvestRA Capital
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases.
BiotechHealthtech
Co-investorsDementia Discovery FundEisai Innovation, Inc.McCarthy CapitalSV Health InvestorsAbbVieBridge Investments+9 more
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB InvestmentAnzu PartnersGrazia Equity GmbHHealthCapSolasta Ventures+3 more
HotSpot Therapeutics develops novel biopharmaceutical products and therapeutic platforms focused on innovative biomedical technologies.
AI & Machine LearningBiotechHealthtech
BoardBruce Booth(Chairman)in
Co-investorsAtlas VentureB Capital GroupB4 CapitalPivotal Life SciencesSofinnova PartnersSolasta Ventures+2 more
.jpeg){kind=logo}
A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.
BiotechHealthtech
Co-investorsFrazier Life SciencesHighlight CapitalXeraya CapitalAmgen VenturesBlackRockBlackstone Life Sciences+5 more
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(Founder)inGlen McIntyre(Founder)Timothy Craven(Founder)
BoardCOREY GOODMAN(Director)inMATT HERSHENSON(Director)in
Co-investorsBEVCCivilization Ventures Management, LlcPlayground GlobalvenBio PartnersAxial VCvenBio Global Strategic
Kymera International manufactures specialty materials and surface technologies, including metal powders, alloys, and advanced coatings, serving industrial customers across aerospace, automotive, electronics, and other sectors globally.
Advanced ManufacturingDeep TechNew MaterialsDetroit, US
Willson Ropp(Chief Executive Officer)in
LAVA develops the Gammabody platform, which generates bispecific antibodies that activate gamma-delta T cells to treat cancer by directing immune cells to tumors and triggering anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical Devices
Ton AdanginHans van der Vliet(Head of Innovation)inSteve Hurly(Chief Executive Officer)Oxana Polyakova(Chief Scientific Officer)in
Co-investorsSanofi VenturesYsios CapitalGilde HealthcareNovo HoldingsREDMILE
LifeMine is a biopharmaceutical company that uses data science and advanced methods to accelerate drug discovery and develop precision medicines across therapeutic areas.
AI & Machine LearningBiotechDeep TechCambridge, US
Gregory L. Verdine(Executive Officer, Director)Gregory Verdine, Ph.D.
BoardHingge Hsu(Executive Officer, Director)Weiqing Zhou(Executive Officer, Director)
Co-investorsARCH Venture PartnersGV (Google Ventures)RA CapitalAisling CapitalAlexandriaBezos Expeditions+7 more
Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.
BiotechMedical Devices
Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in
Co-investorsARCH Venture PartnersJDRF T1D FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova PartnersAbbVie+7 more
Myoventive develops RNA-based medicines to treat genetic heart diseases.
BiotechSouth San Francisco, US
Co-investorsvenBio Partners
Developing novel KRAS degraders.
Burlington, US
Huaixiang Hao(Founder)in
Co-investorsBioTrack CapitalJJDC
Teambit analyzes code, meeting time, and interactions to measure and improve the performance of software development teams, delivering objective metrics.
AI & Machine LearningDeveloper ToolsSaaS
Paula Enei(Founder)in
Co-investorsGG Capital4BIO CapitalDeerfield Management CompanyGeneral CatalystNorwest Venture PartnersNovo Holdings
.png)
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.
BiotechHealthtechMedical DevicesBurlingame, US
Hong Wan(Executive Officer, Director)in
BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)Corey Goodman(Director)in
Co-investorsLightstone VenturesvenBio PartnersMatrix Partners ChinavenBio Global Strategic
Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines, with a focus on immunology and the immune system.
AI & Machine LearningBiotechHealthtech
Co-investorsNew Enterprise Associates (NEA)Rho VenturesSanofi VenturesFJ Labs
Viridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit.
BiotechDigital HealthMedical DevicesWaltham, US
Jonathan Violin(Executive Officer, Director)in
BoardPeter Harwin(Director)Tomas Kiselak(Director)
Co-investorsBroadview VenturesLongitude Capital
A biologics center of excellence focused on developing and delivering medicines to patients, operating as a subsidiary within the Otsuka pharmaceutical group.
AI & Machine LearningBiotechHealthtechMedical Devices
Zachary Shriver(President and Chief Executive Officer)Karthik Viswanathan(Vice President, Research)in
Co-investorsCTI Life Sciences Fund L.P.Cycad Group LLCLux Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
ADRxAnavo TherapeuticsAxonisEyeBioGlobal Health Innovation FundImago BioSciences, Inc.LifeMinePhotysRay TherapeuticsTopoTranslate BioVectorY Therapeutics
Exits · 13
7 IPOs · 6 acquisitionsAktis OncologyNASDAQ: AKTSAlectorNASDAQ: ALECEntrada Therapeutics, Inc.NASDAQ: TRDAInvivydNASDAQ: IVVDKymera TherapeuticsNASDAQ: KYMRSpero TherapeuticsNASDAQ: SPROXilio TherapeuticsNASDAQ: XLOCarawayacq. by MerckEyeBioacq. by MerckImagoacq. by MerckTidal Therapeuticsacq. by SanofiTranslate Bioacq. by SanofiVISTERRA, INC.acq. by Otsuka
Portfolio news
latest coverage across their companiesInvivyd · investors.invivyd.com · Sep 1, 2026
Platanus · altss.com · Aug 11, 2026
LifeMine Therapeutics · finsmes.com · Aug 8, 2026
Spero Therapeutics · stocktitan.net · Jul 14, 2026
PAQ Therapeutics · finsmes.com · Jan 26, 2026
IPO stake values · per SEC filings · 4
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Alector | 4.6% | $25.00 | Jan 2020 | $88.6M |
| Entrada Therapeutics, Inc. | 5.8% | $20.00 | Nov 2021 | $34.8M |
| Xilio Therapeutics | 3.7% | $16.00 | Oct 2021 | $15.7M |
| Spero Therapeutics | 5.2% | $12.50 | Jul 2018 | $11.7M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has MRL Ventures Fund made?
- MRL Ventures Fund has 43 tracked investments, 13 of which have exited, including 5 dated in the last 24 months.
- What stage does MRL Ventures Fund invest at?
- MRL Ventures Fund invests at the Pre-Seed, Seed stages.
- What is MRL Ventures Fund's typical check size?
- MRL Ventures Fund typically writes checks of $25M.
- What sectors does MRL Ventures Fund focus on?
- MRL Ventures Fund focuses on Biotech, Healthtech, Medical Devices.
- Where is MRL Ventures Fund located?
- MRL Ventures Fund is headquartered in Cambridge, US.
- Does MRL Ventures Fund lead rounds?
- Yes, MRL Ventures Fund leads investment rounds.
- Who does MRL Ventures Fund co-invest with?
- MRL Ventures Fund most often shares deals with RA Capital, SV Health Investors, Bain Capital Life Sciences, among 73 tracked co-investors.
Co-investors · 2
RA Capital Management is a healthcare and planetary health investment firm that founds, funds, and scales companies using scientific diligence, multi-stage capital, and hands-on operational support.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Firms observed investing alongside MRL Ventures Fund, from public investor directories. Shared companies are the overlap with MRL Ventures Fund's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Blackbird is a venture capital firm that backs founders from the earliest stages, with a focus on ambitious technology startups across Australia and New Zealand.
Breyer Capital is an early-stage, high-conviction investment firm with a dedicated healthcare and life sciences practice backing founders rebuilding medicine at the intersection of science, data, care delivery, and economics.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.